Published on 28 Oct 2021 on Benzinga via Yahoo Finance
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is trading significantly higher Tuesday after the company announced the successful completion of the discovery phase for its next preclinical pipeline candidate, SON-1410.
The candidate represents Sonnet BioTherapeutics' second bispecific compound integrating Interleukin 12 with the company's Fully Human Albumin Binding platform. The target indications for SON-1410 will be melanoma and renal cancers.